Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Fautrel

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
RMD Open|May 7, 2020
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparisonB Fautrel, B Zhu, P C Taylor, et al.
Arthritis Care & Research|March 26, 2014
Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohortFlorence Canouï-Poitrine, Cécile Poulain, Anna Molto, et al.
Annals of the Rheumatic Diseases|December 24, 2010
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registryD Salmon-Ceron, F Tubach, O Lortholary, et al.
Annals of the Rheumatic Diseases|July 5, 2005
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of RheumatologyX Le Loët, J M Berthelot, A Cantagrel, et al.
Annals of the Rheumatic Diseases|October 20, 2007
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in FranceT Lequerré, P Quartier, D Rosellini, et al.
Osteoarthritis and Cartilage|January 23, 2022
Development and validation of the Flare-OA questionnaire for measuring flare in knee and hip osteoarthritisY Traore, J Epstein, E Spitz, et al.
Annals of the Rheumatic Diseases|April 1, 2005
Prevalence of rheumatoid arthritis in France: 2001F Guillemin, A Saraux, P Guggenbuhl, et al.
Annals of the Rheumatic Diseases|April 9, 2005
Prevalence of spondyloarthropathies in France: 2001A Saraux, F Guillemin, P Guggenbuhl, et al.
Annals of the Rheumatic Diseases|May 19, 2016
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologistsM Hifinger, M Hiligsmann, S Ramiro, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
RMD Open|May 7, 2020
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparisonB Fautrel, B Zhu, P C Taylor, et al.
Arthritis Care & Research|March 26, 2014
Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohortFlorence Canouï-Poitrine, Cécile Poulain, Anna Molto, et al.
Annals of the Rheumatic Diseases|December 24, 2010
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registryD Salmon-Ceron, F Tubach, O Lortholary, et al.
Annals of the Rheumatic Diseases|July 5, 2005
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of RheumatologyX Le Loët, J M Berthelot, A Cantagrel, et al.
Annals of the Rheumatic Diseases|October 20, 2007
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in FranceT Lequerré, P Quartier, D Rosellini, et al.
Osteoarthritis and Cartilage|January 23, 2022
Development and validation of the Flare-OA questionnaire for measuring flare in knee and hip osteoarthritisY Traore, J Epstein, E Spitz, et al.
Annals of the Rheumatic Diseases|April 1, 2005
Prevalence of rheumatoid arthritis in France: 2001F Guillemin, A Saraux, P Guggenbuhl, et al.
Annals of the Rheumatic Diseases|April 9, 2005
Prevalence of spondyloarthropathies in France: 2001A Saraux, F Guillemin, P Guggenbuhl, et al.
Annals of the Rheumatic Diseases|May 19, 2016
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologistsM Hifinger, M Hiligsmann, S Ramiro, et al.
Pageof 6